VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE
July 26-27, 2001
Slides
Aviron Live Attenuated Influenza Virus Vaccine, FluMistâ„¢
FDA Slides
Aviron Cold-Adapted Live Attenuated Influenza Virus Vaccines, Trivalent FluMistâ„¢, FDA Clinical Summary, ChrisAnna M Mink, MD, FDA ppt htm
Overview of Development of Cold Adapted, Live Attenuated influenza Vaccines; basis for Attenuation; and Potential for Reassortment with Wild-Type Viruses in Nature, Dr. Brian Murphy, NIH pdf
Session 2: Introduction, Peter A Patriarca, MD, FDA ppt htm
Sponsor Slides
Disclaimer
The statements contained in this document are those of the product's sponsor,
not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA
has not made a final determination about the safety or effectiveness of the
product described in this document.
Introduction, Harry Greenberg, MD, Aviron pdf
Large Scale Safety in Healthy Children, The Kaiser Study - AV019, Steven Black, MD & Henry Shinefield, MD, Northern California Kaiser Permanente Vaccine Study Center pdf
Safety in Children, Paul M Mendelman, MD, Aviron pdf
Safety in Adults, Paul M Mendelman, MD, Aviron pdf
Efficacy and Effectiveness in Healthy Adults, Kristin L Nichol, MD, MPH, MBA, University of Minnesota and the Minneapolis VA Medical Center pdf
Efficacy in Children, Robert B Belshe, MD, Saint Louis University pdf
Conclusions & Contributors, Harry Greenberg, MD, Aviron pdf